



12-21-05

CASE 4-31394B

IPo

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 483668745 US
Express Mail Label Number

December 20, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
RONALD EDWARD STEELE
APPLICATION NO: 10/826,106
FILED: APRIL 15, 2004
FOR: COMBINATION OF ORGANIC COMPOUNDS

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed June 25, 2004. Since Applicant believes this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Gregory D. Ferraro
Attorney for Applicant
Reg. No. 36,134

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7831

Date: December 6, 2005

20
ff

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

DEC 20 2005

ATTY. DOCKET NO.
4-31394B
APPLICATION NO.
10/826,106
APPLICANT
Ronald Edward Steele
FILING DATE
APRIL 15, 2004

Group

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE |
|------------------|-----------------|---------|-----------------|-------|----------|-------------|
| AA | 5,795,909 | 8/18/98 | Shashoua et al. | 514 | 449 | 5/22/96 |
| AB | | | | | | |
| AC | | | | | | |
| AD | | | | | | |
| AE | | | | | | |
| AF | | | | | | |
| AG | | | | | | |
| AH | | | | | | |
| AI | | | | | | |
| AJ | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/> |
|----|-----------------|----------|--------|-------|----------|---|
| AK | WO 96/40257 | 12/19/96 | WIPO | | | <input type="checkbox"/> <input type="checkbox"/> |
| AL | WO 96/40258 | 12/19/98 | WIPO | | | <input type="checkbox"/> <input type="checkbox"/> |
| AM | | | | | | <input type="checkbox"/> <input type="checkbox"/> |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

| | |
|----|---|
| AN | Beers et al., The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, pp 1628-1693 and 1840-1848 |
| AO | Results for Registry No. 135070-05-2 STN Registry File, Retrieved from STN 2005-06-17 (1 page) |
| AP | Furet et al., Aromatase Inhibitors: Synthesis, Biological Activity and Binding Mode of Azole-Type Compounds, Journal of Medicinal Chemistry, No. 36: pp 1393-1400 (1993) |
| AQ | Trunet et al., The Effects of Fadrozole Hydrochloride on Aldosterone Secretion in Healthy Male Subjects, Journal of Clinical Endocrinology and Metabolism, 74(3) pp 571-576 (1992) |
| AR | Haeusler et al., Evidence that corticosterone is not an obligatory Intermediate in Aldosterone biosynthesis in the Rat Adrenal. Journal of steroid Biochemistry, 34 (1-6) pp. 567-570 (1989). |

| EXAMINER | DATE CONSIDERED |
|----------|-----------------|
|----------|-----------------|

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.